Salmah Binti Bahri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salmah Binti Bahri has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Affarizan Bin Sidek1 shared publication
- Anand Jha
Novartis Oncology, 20 Pasir Panjang Road, #10-25/28 Mapletree Business City, Singapore, 117439, Singapore
1 shared publication - Bor-Sheng Ko
Division of Hematology Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
1 shared publication - Chuo Yew Ting
Pharmaceutical Services Division, Sarawak State Health Department, Ministry of Health, Kuching, Malaysia
1 shared publication - Diana MacDonell
Pharmaceutical Benefits Advisory, Bedford Park, Australia
1 shared publication - Dong-Churl Suh
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
1 shared publication
Latest Publications
- 14 June 2019
- Published by Emerald Publishing in International Journal of Pharmaceutical and Healthcare Marketing
- Vol. 13 (3) , 387-402
Consumer behaviour towards pharmaceutical products: a model development
Purpose: Despite the extant literature on purchasing behaviour, little is known about why and how consumers purchase and use pharmaceutical products in Malaysia. This paper aims to develop a holistic model that articulates the factors underlying pharmaceutical product purchase and use and their relationships. Design/methodology/approach: Drawing upon the grounded theory approach, in-depth interviews and analysis on the basis of theoretical saturation were conducted. Enumerators, trained to perform interviews, the transcription and content analysis, sampled 120 Malaysian consumers in the first phase and 40 in the second. ATLAS.ti was used to assist the coding and analytical process. Findings: The findings largely support extant literature on purchasing decisions. Particularly, the evaluation of product attributes was found to be an immediate determinant of purchase and use. The effect, in turn, was moderated by personal factors and facilitating conditions. The need for healthcare products and the knowledge about them were constructed as antecedents in the model. The study also highlights that consumers’ purchase and use of pharmaceutical products could be better understood and managed with a holistic view of the decision-making process. Originality/value: This study proposes the conbe-hepro model to explicate the antecedents and determinants of consumers’ purchase and use of pharmaceutical products in the Malaysian context. It provides a theoretical grounding that enriches our knowledge of the changing behaviour of consumers in healthcare literature. It also yields practical insights to the government bodies and the healthcare providers in Malaysia and other developing countries.
- 14 June 2019
- Published by Emerald Publishing in International Journal of Pharmaceutical and Healthcare Marketing
- Vol. 13 (3) , 387-402
Consumer behaviour towards pharmaceutical products: a model development
Purpose: Despite the extant literature on purchasing behaviour, little is known about why and how consumers purchase and use pharmaceutical products in Malaysia. This paper aims to develop a holistic model that articulates the factors underlying pharmaceutical product purchase and use and their relationships. Design/methodology/approach: Drawing upon the grounded theory approach, in-depth interviews and analysis on the basis of theoretical saturation were conducted. Enumerators, trained to perform interviews, the transcription and content analysis, sampled 120 Malaysian consumers in the first phase and 40 in the second. ATLAS.ti was used to assist the coding and analytical process. Findings: The findings largely support extant literature on purchasing decisions. Particularly, the evaluation of product attributes was found to be an immediate determinant of purchase and use. The effect, in turn, was moderated by personal factors and facilitating conditions. The need for healthcare products and the knowledge about them were constructed as antecedents in the model. The study also highlights that consumers’ purchase and use of pharmaceutical products could be better understood and managed with a holistic view of the decision-making process. Originality/value: This study proposes the conbe-hepro model to explicate the antecedents and determinants of consumers’ purchase and use of pharmaceutical products in the Malaysian context. It provides a theoretical grounding that enriches our knowledge of the changing behaviour of consumers in healthcare literature. It also yields practical insights to the government bodies and the healthcare providers in Malaysia and other developing countries.
- Open Access
- 16 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 137
A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region
This article is a call for action to the relevant stakeholders to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region by looking into three main areas: (a) developing legislative definitions to confer enforceable protection, (b) creating or strengthening policies by objectively measuring the impact brought about by rare diseases and establishing platforms to reach out to the rare disease community, and (c) fostering collaboration across sectors and countries. It is hoped that these suggested actions can catalyze discussions and progress in the region.
- 16 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 137
Open AccessA call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region
This article is a call for action to the relevant stakeholders to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region by looking into three main areas: (a) developing legislative definitions to confer enforceable protection, (b) creating or strengthening policies by objectively measuring the impact brought about by rare diseases and establishing platforms to reach out to the rare disease community, and (c) fostering collaboration across sectors and countries. It is hoped that these suggested actions can catalyze discussions and progress in the region.